早期类风湿关节炎患者接受培塞利珠单抗治疗一年后继续、减量或停药的III期研究
在未使用过改善病情抗风湿药的早期RA患者中,经培塞利珠单抗标准剂量联合优化甲氨蝶呤治疗1年并达到持续低疾病活动度后,再随机分为继续标准剂量、减量频率或停用培塞利珠单抗三组。研究未达到主要终点,但标准剂量和减量频率组维持低疾病活动度的比例均高于停药组。
要点
- 研究未达到主要终点:标准剂量组与停药组维持低疾病活动度比例差异无统计学意义。
- 减量频率组维持低疾病活动度比例显著高于停药组(53.2% vs 39.2%,P=0.041)。
- 标准剂量与减量频率组在影像学无进展和身体功能正常方面数值上均高于停药组。
核心结论
- 研究未能达到主要终点,但培塞利珠单抗标准剂量或减量频率联合甲氨蝶呤在维持低疾病活动度方面均优于停用培塞利珠单抗。
- 标准剂量与减量频率剂量之间无临床意义差异。
研究设计与样本
- III期研究,对完成第1年培塞利珠单抗标准剂量(200mg每2周)联合优化甲氨蝶呤治疗并达到持续低疾病活动度(第40周和第52周DAS28-ESR均≤3.2)的早期RA患者进行再随机。
- 293例患者按2:3:2再随机分为培塞利珠单抗标准剂量组(n=84)、减量频率组(n=127)或安慰剂联合甲氨蝶呤组(n=82)。
- 主要终点为第52-104周期间维持低疾病活动度且无复发的患者百分比。
主要发现
- 标准剂量组、减量频率组和停药组维持低疾病活动度的比例分别为48.8%、53.2%和39.2%(标准剂量 vs 停药 P=0.112;减量频率 vs 停药 P=0.041)。
- 影像学无进展(mTSS较基线变化≤0.5)比例分别为79.2%、77.9%和70.3%。
- 身体功能正常(HAQ-DI≤0.5)比例分别为71.4%、70.6%和57.0%。
- 各组安全性特征相似,继续培塞利珠单抗至第104周未发现新的安全性信号,无死亡报告。
关键数值与推荐
- 持续低疾病活动度定义为第40周和第52周DAS28-ESR均≤3.2。
- 低疾病活动度维持定义为第52-104周期间无复发。
- 影像学无进展定义为mTSS较基线变化≤0.5。
- 身体功能正常定义为HAQ-DI评分≤0.5。
临床怎么用
- 对于早期RA患者,经培塞利珠单抗联合甲氨蝶呤治疗1年达到持续低疾病活动度后,继续使用培塞利珠单抗(标准剂量或减量频率)比停药更能维持疗效。
- 标准剂量与减量频率剂量疗效相当,可考虑减量频率方案。
局限性
- 第1期纳入患者数比预期少36%,导致第2期合格患者数减少。
- 主要终点未达到,标准剂量与停药组比较差异无统计学意义(P=0.112)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In disease-modifying antirheumatic drug-naive patients with early rheumatoid arthritis (RA) who had achieved sustained low disease activity (a Disease Activity Score in 28 joints using the erythrocyte sedimentation rate of ≤3.2 at both week 40 and week 52) after 1 year of treatment with certolizumab pegol (CZP) at a standard dose (200 mg every 2 weeks plus optimized methotrexate [MTX]), we evaluated whether continuation of CZP treatment at a standard dose or at a reduced frequency (200 mg every 4 weeks plus MTX) was superior to stopping CZP (placebo plus MTX) in maintaining low disease activity for 1 additional year. METHODS: A total of 293 patients from period 1 of our study were re-randomized 2:3:2 in period 2 to CZP at a standard dose (n = 84), CZP at a reduced frequency (n = 127), or placebo plus MTX (CZP stopped) (n = 82). The primary end point was the percentage of patients who maintained low disease activity throughout weeks 52-104 without flares. We used a hierarchical testing scheme, comparing CZP at a standard dose with CZP stopped. If P < 0.05 was achieved, then CZP at a reduced frequency was compared with CZP stopped (nonresponder imputation). RESULTS: The 293 patients from period 1 represented 36% fewer patients than projected, yielding a smaller number of patients eligible for period 2. Higher proportions of patients treated with the standard and reduced frequency regimens maintained low disease activity than those who had stopped CZP (48.8% and 53.2%, respectively, versus 39.2% [P = 0.112 and P = 0.041, respectively; nominal P value, first hierarchical test not significant]). Similar trends were observed for radiographic nonprogression (change from baseline of ≤0.5 in modified Sharp/van der Heijde score; 79.2% and 77.9% of patients, respectively, versus 70.3%) and normative physical function (Health Assessment Questionnaire disability index score of ≤0.5; 71.4% and 70.6% of patients, respectively, versus 57.0%). Safety profiles were similar between all groups, with no new safety signals identified for continuing CZP to week 104. No deaths were reported. CONCLUSION: The study failed to meet its primary end point. However, there were no clinically meaningful differences between the standard and reduced frequency doses of CZP plus MTX; both controlled RA more effectively than stopping CZP.
引用
- Weinblatt ME, Bingham CO, Burmester GR, et al. A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. Arthritis Rheumatol. 2017. PMID: 28666080. doi:10.1002/art.40196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。